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Background: ZAP70 gene expression is associated with poor prognosis in B-cell lymphoproliferative disorders
especially chronic lymphocytic leukaemia (CLL) but its role in adult B-ALL has not been established. On diagnostic
samples from 76 patients with adult ALL (65 with B-ALL and 11 with T-ALL) ZAP70 mRNA expression levels were
studied by real time-quantitative PCR (RT-qPCR) analysis.
Findings: A broad distribution of ZAP70 expression was observed in ALL, ranging from 0.002 to 5.3 fold that of the
ZAP70 positive Jurkat reference cell line. No association was observed between expression levels and the presence
of specific cytogenetic abnormalities. Five cases, including one case of T-ALL, had ZAP70 expression above the level
of the Jurkat reference cell line.
Conclusions: Our results confirm the frequent expression of ZAP70 in adult ALL. Limited comparisons made did
highlight poor-risk patients with high ZAP70 expression, but due to lack of clinical information on patient samples
we were unable to directly assess the impact on disease prognosis. ZAP-70 may be an important laboratory assay in
adult ALL and further studies are warranted to study a potential correlation with cytogenetic and other genetic
markers.
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Zeta associated protein tyrosine kinase (ZAP70) is a 70kD
molecule associated with the ζ-chain of the CD3 T-cell re-
ceptor (TCR) complex [1]. On formation of the immuno-
logical synapse, immune receptor tyrosine-based
activation motifs (ITAM) in the CD3 and ζ-chains are
activated by phosphorylation. The ζ-chains become
docking sites for ZAP70 thereby activating the MAP
kinase, calcium/calcineurin and protein kinase C signalling
pathways. Thus ZAP70 plays a major part in lymphocyte
signal transduction resulting in cell differentiation and
proliferation [2].
ZAP70 gene expression plays a critical role in the transi-
tion of pre-B to pro-B cells within the bone marrow.
Genetic inactivation of the ZAP70 gene results in failure
of pre-B cell receptor (pre-BCR) induced differentiation,
proliferation and heavy chain exclusion, and a failure to* Correspondence: geothy@doctors.org.uk
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distribution, and reproduction in any mediumprogress beyond the pre-B cell stage [3]. ZAP70 is not
expressed in normal mature B cells derived from bone
marrow, peripheral blood, or tonsil [4]. ZAP70 expression
is also observed in a large proportion of patients with
chronic lymphocytic leukaemia (CLL) where it has been
associated with poor clinical outcome in several studies
[5]. More recently, ZAP70 protein has been detected in a
wide variety of additional B-cell lymphoproliferative disor-
ders including mantle cell lymphoma, diffuse large B-cell
lymphoma, and Burkitt lymphoma [6,7].
While several groups, including our own, have demon-
strated ZAP70 mRNA expression in paediatric pre-B ALL
[8], there have been no previous studies that have used
RT-qPCR to determine ZAP70 expression in adult cases of
ALL and then correlated the results with cytogenetic ab-
normalities at diagnosis. In the present work we have used
RT-qPCR analysis to determine the expression of ZAP70
mRNA levels in 76 adult patients with B-ALL or T-ALL at
the time of diagnosis. We show that ZAP70 gene expres-
sion is detected in almost all cases with a broad range ofentral Ltd. This is an Open Access article distributed under the terms of the
creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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observed between ZAP70 expression and cytogenetic ab-
normalities identified in these patients.Results
In total we examined 76 cases of ALL, of which 65 were
of B-cell origin (B-ALL) and 11 of T-cell origin (T-ALL).
ZAP70 mRNA expression was measured as fold in-
crease/decrease relative to expression levels in the refer-
ence ZAP70 positive Jurkat cell line Table 1. A broad
range of distribution of ZAP70 mRNA expression (range
0.002-5.36; median 0.169; mean 0.306) (Figure 1a) was
observed. As expected, ZAP70 expression was seen in all
cases of T-ALL (range 0.09-2.955; median 0.233; mean
0.504) (Figure 1b). Overall, 5 cases (4 B-ALL, 1 T-ALL)
expressed ZAP70 at higher levels than the reference
ZAP70 positive Jurkat cell line (Figure 1b).
We then searched for potential correlations between
ZAP70 expression and known genetic abnormalities
within the B-ALL tumours. 53/65 (82%) in the B-ALL
group had cytogenetic changes such as t(9;22) (n= 18), 9p
abnormality (n= 12), t(1;19) TCF3-PBX1 gene fusion, (pre-
viously called E2A-PBX1) (n= 3) and a range of other ab-
normalities, including Burkitt lymphoma, hyperdiploidy,
hypodiploidy, monosomy 7 and 12p abnormality (n= 20).
12 cases of B-ALL had no observable cytogenetic abnor-
mality. No association was observed between the level of
ZAP70 expression and individual cytogenetic subgroups
(Figure 1c), although we noted a statistically insignificant
trend towards increased levels of ZAP70 mRNA in cases
with monosomy 7 and 12p abnormalities (data not
shown). No association was found between ZAP70 mRNA
expression and the ZAP70 copy numbers based on cyto-
genetic data (Additional file 1).Table 1 Patient demographic and cytogenetic data
Type Cytogenetics Cases M/F Agea ZA
T-ALL 11 6/5 44.7; (19-56) 0.3
B-ALL 65 36/29 46.0; (18-79) 0.3
B-ALL t(9;22) 18 10/8 44.4; (23-70) 0.4
B-ALL t(1;19)TCF3-PBX1 3 2/1 43.3; (42-52) 0.2
B-ALL 9p abnormality 12 8/4 45.2; (18-72) 0.1
B-ALL Burkitt lymphoma 6 3/3 44.7; (22-78) 0.1
B-ALL Hyperdiploid 6 5/1 45.9; (22-76) 0.2
B-ALL Monosomy 7 4 1/3 44.9; (37-58) 0.1
B-ALL Hypodiploid 3 1/2 43.7; (18-79) 0.1
B-ALL MLL/AFF1 1 1 30.0 0.0
B-ALL Normal 46, XX or 46, XY 12 6/6 46.7; (18-82) 0.1
a Mean patient age in years (range).
b ZAP70 RNA expression was quantified by RT-qPCR and the normalised values exp
median and range for each sub-group.While a relatively continuous distribution pattern of
ZAP70 mRNA levels was seen across the B-ALL cohort, the
level of expression was markedly increased in 4 cases, with
values ranging from 1.1-5.4 (mean 2.4). Of these B-ALL
patients, two had complex cytogenetics whilst the other two
had t(9,22) translocations thus predicting poor outcomes in
all four cases [9]; however the remaining 16 patients who
carried a t(9;22) cytogenetic abnormality had ZAP70 ex-
pression levels within the main distribution. Similar to CLL
patients where a high ZAP70 expression level is associated
with a poor prognosis, ZAP70 mRNA expression may be
relevant to the prognosis of patients with B-ALL.Discussion
This is the first distribution profile for ZAP70 mRNA ex-
pression in adult B-lineage ALL patients by RT-qPCR. The
results demonstrate a broad range of expression and a
markedly increased expression in a small proportion of
cases (6%). Chiaretti et al. [10] used microarray analysis to
determine ZAP70 mRNA expression in 95 adult ALL cases
followed by immunoblotting to confirm protein expression.
In their study, relatively high ZAP70 expression levels were
observed in patients with the t(1;19) TCF3-PBX1 gene
rearrangement but similar high ZAP70 levels were not seen
in our cohort. CDKN2A, a tumour suppressor gene on
chromosome 9, can be inactivated by deletion, mutation or
methylation. Its role in B-ALL is currently under dispute
and has been identified by some groups to have a
prognostic role in childhood and adult ALL [11-15]. We
analysed patients with 9p abnormalities, without t(9;22),
t(1;19), t(8;14), and found no association with ZAP70
mRNA levels.
Although the biochemical basis for the correlation be-
tween ZAP70 expression and poor prognostic aggressiveP70 expressionb Associated abnormalities
63; 0.252; (0.090-2.955) 9p abnormality(n = 5)6q deletion (n = 2t(10;14)
(n = 1)
32; 0.185; (0.002-5.360)
40; 0.191; (0.010-5.360) Hyperdiploid (n = 2), Monosomy 7 (n = 2)9p
abnormality (n = 3)12p gain (n = 2)t(1;19) (n = 1)
19; 0.210; (0.193-0.254) 9p abnormality (n = 2)6q deletion (n = 2)
80; 0.176; (0.004-0.535) Monosomy7 (n = 2)RUNX1 (n = 2)12p
abnormality (n = 3)6q deletion (n = 2)
59; 0.168; (0.005-0.350) 12p abnormality (n = 1)9p abnormality (n = 2)
32; 0.184; (0.004-1.383)
77; 0.182; (0.015-0.399) 12p abnormality (n = 1)
73; 0.182; (0.067-0.290) 12p abnormality (n = 1)
89 12p abnormality
40; 0.100; (0.002-0.291)
ressed relative to that seen in Jurkat control cells. Data shown are mean,
Figure 1 ZAP70expression in adult ALL patients. (a) ZAP70 RNA expression in adult ALL patients quantified by RT-qPCR. (b) ZAP70 expression
in combined adult B-ALL and T-ALL patient cohorts. (c) ZAP70 expression in adult B-ALL patients classified into different cytogenetic groups. The
cytogenetic group classified as others includes Burkitt lymphoma, hyperdiploid, hypodiploid, monosomy 7 and MLL/AFF1. In each panel, ZAP70
mRNA levels were normalised to GAPDH expression and then reported as a fold increase/decrease relative to ZAP70 expression in the Jurkat cell
line (set as an arbitrary value of 1.0); n = number of patients.
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enhanced signal transduction through the pre-BCR com-
plex and phosphorylation of phosphotyrosine phosphat-
ase has been observed [16]. Unfortunately clinical
information on patients recruited into this study could
not be obtained, though the cytogenetic information on
patients with high ZAP70 mRNA levels suggests possible
inferior outcomes. This potential association of high
ZAP70 mRNA levels with inferior outcomes may not beindependent, as the cytogenetic findings in the four
patients with the highest ZAP70 expression, i.e. complex
or t(9;22), also predict a poor prognosis. However cyto-
genetic assessment can be difficult [17] and therefore
ZAP70 mRNA expression levels may have a role as an
alternative prognostic marker in patients with adult B-
ALL. This in turn may allow escalation or de-escalation
of therapeutic strategies as well as the possibility of using
the ZAP70-specific inhibitor, Piceatannol [18] as an
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ALL patients addressing the role of ZAP70 mRNA ex-
pression levels in association with cytogenetic and other
genetic markers are hence warranted.
Methods
Patient samples
Bone marrow specimens were collected at disease presenta-
tion from adult ALL patients attending various centres in
West Midlands, UK and referred to the West Midlands Re-
gional Genetics Laboratory between 1998 and 2005, as part
of routine genetic analysis of the leukaemias. Bone marrow
mononuclear cells (BMMC) were isolated either by Ficoll
density centrifugation or by red cell lysis using Erythrocyte
Lysis Buffer (Qiagen, Crawley, UK). BMMC were lysed and
total RNA was recovered in 60 μl RNAse free water using
QIAamp spin columns (QIAamp RNA Blood Mini Kit,
Qiagen, Crawley, UK). Excess material after diagnostic
testing was stored within the ethically approved Central
England Haemato-oncology Research Biobank (REC refer-
ence: 09/H0405/12). Anonymised cDNA samples from the
biobank were used for the ZAP70 study. Samples included
in the study were from consecutive cases where sufficient
excess material remained in patients older than 16.
Routine cytogenetics, FISH and endpoint RT-PCR
Cytogenetic analysis was performed as part of routine ana-
lysis using standard methods (G-banding). FISH analysis for
MLL rearrangements, BCR-ABL1 gene fusions, and ETV6-
RUNX1 gene fusion was routinely performed on all ALL
samples [17], using commercial probes following manufac-
turer’s protocols (Vysis LSI MLL Dual Color, Break Apart
Rearrangement Probe; Vysis LSI BCR/ABL Dual Color,
Dual Fusion Translocation Probe; Vysis LSI ETV6(TEL)/
RUNX1(AML1) ES Dual Color Translocation Probe Set)
(Abbott Molecular, Illinois, USA). In addition, other FISH
probes were used variably due to suspicion on G-band ana-
lysis and changes in routine FISH screening policies during
the period when the samples were collected (Vysis LSI p16
(9p21) SpectrumOrange/CEP 9 SpectrumGreen Probe;
MYC Break Apart FISH Probe Kit; IGH/MYC/CEP 8 Tri-
Color DF FISH Probe Kit; LSI IGH Dual Color, Break Apart
Rearrangement Probe; CEP4 and CEP10 probes (Abbott
Molecular, Illinois, USA); and Dako SIL-TAL1 FISH DNA
Probe, Sub-Deletion Signal (Dako, Glostrup, Denmark)).
End-point RT-PCR for BCR-ABL1 transcripts was per-
formed routinely using standard procedures [19].
Quantification of ZAP70 expression by RT-qPCR
Relative quantitation of ZAP70 mRNA expression was
performed using an ABI 7700 Sequence Detection System
(Applied Biosystems UK) and analysed using SDS software
1.7. ZAP70 transcripts were detected using the following
primers and probe: forward primer 5'-CGCTGCACAAGTTCCTGGT-3', reverse primer 5'-GACACCTGGT
GCAGCAGCT-3', Taqman probe 5'-(FAM)-CATTGC
TCACAGGGATCTCCTCCCTCT-(TAMRA)-3'. GAPDH
transcripts, which served as an internal control, were
quantified using a commercial assay (Applied Biosystems,
U.K.). PCR amplification and data normalisation were per-
formed as previously described [8]. These normalised
ZAP70 to GAPDH ratios were then calculated as a fold
change relative to the ZAP70 to GAPDH ratio of the
ZAP70 positive Jurkat T-cell line, defined as having an ex-
pression level of 1.0. All test samples were run in duplicate
(mean values used) and template-negative samples served
as control and were always negative.
Statistical analysis
Statistical analysis was performed by group comparison
using either a two-sample test or ANOVA and correlation
analysis was evaluated with Pearson coefficient, using
GraphPad Prism 4 and SPSS software.
Additional file
Additional file 1: Table S1. ZAP70 expression data and cytogenetic
analysis of individual ALL samples.
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